AstraZeneca needs new strategy after boardroom shake up

Source EP Vantage
Company AstraZenecaArdea BiosciencesThe Medicines Company 
Date April 26, 2012

Whoever becomes the new chief executive of AstraZeneca faces a difficult task - choosing a path to pursue to resuscitate the ailing Anglo-Swedish drug maker’s growth prospects. Options include a transformative acquisition, an outright sale of the company, or continuation of its current strategy of investing in R&D and smaller bolt-ons and hoping for a better success rate. None of them will provide an easy fix.

Astra now faces a tumultuous period until a permanent successor is announced to David Brennan, who has quit suddenly amid investor disquiet after six years in the job. While very effective at driving improvements in shareholder returns and profitability, Mr Brennan failed to do enough to protect the top line from inevitable patent expiries. Today’s disastrous first-quarter results, with sales of key products disappointing and a big downgrade to this year’s earnings forecast, illustrate the challenges that await his replacement.

You are a Guest User

The remainder of this story is only available to EP Vantage Subscribers.

Please click the following link to register for a free trial of EP Vantage

Register for a free trial

or if you are already a registered user, please Login Now

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM
©2014 EP Vantage Ltd